

Is Xanax still in shortage in 2026? Get the latest Alprazolam availability update, what's causing supply issues, costs, and how to find it in stock.
If you've been struggling to fill your Alprazolam prescription, you're probably wondering: is Xanax still in shortage?
The short answer is complicated. Alprazolam isn't always listed as a formal shortage on the FDA's drug shortage database, but patients across the country continue to report difficulty finding it at their local pharmacies — particularly certain strengths like the 1 mg and 2 mg tablets.
In this update, we'll cover the current state of Xanax availability in 2026, explain what's driving the ongoing supply challenges, break down current costs, and show you how to find Alprazolam in stock.
Alprazolam supply has been uneven since the COVID-19 pandemic began in 2020. Here's a timeline of the key events:
So while you may not see "Alprazolam" on the FDA shortage list every month, the real-world experience for many patients is that finding it remains a challenge.
Several factors continue to affect Alprazolam availability:
As a Schedule IV controlled substance, Alprazolam production is capped annually by the DEA. These quotas are set based on projected medical need, but they don't always keep pace with actual demand — especially when anxiety disorder diagnoses continue to rise.
Alprazolam is made by many generic manufacturers including Greenstone, Sandoz, Mylan, Teva, and Aurobindo. When one manufacturer has a production issue, the shortage may only affect certain pharmacies that primarily stock from that supplier.
Many chain pharmacies limit how much of any controlled substance they keep on hand. This creates situations where Alprazolam is technically available from distributors but not on pharmacy shelves.
More Americans than ever are being treated for anxiety and panic disorders. The increased prescribing volume continues to put pressure on supply. For a deeper dive into why this medication is scarce, read Why Is Xanax So Hard to Find?
Cost depends on whether you have insurance and whether you're filling brand-name Xanax or generic Alprazolam.
With a discount card from GoodRx, SingleCare, or similar services, you may pay as little as $5-$15 for a 30-day supply.
Brand-name Xanax, if available, can cost $400-$1,000+ for 30 tablets. Most patients fill the generic, which is therapeutically equivalent.
Generic Alprazolam is typically covered on most insurance plans as a Tier 1 or Tier 2 medication. Your copay may be as low as $0-$15 depending on your plan. Some insurers may require prior authorization for higher quantities.
For more ways to save, see our full guide: How to Save Money on Xanax in 2026.
The main formulations of Alprazolam remain the same:
If one formulation is unavailable, ask your doctor whether another might work for you. Sometimes switching from IR to XR (or vice versa) can solve an availability problem.
There are also alternative medications worth considering if Alprazolam remains hard to find. Read about them in our alternatives to Xanax guide.
Here are the most effective strategies:
For detailed strategies, see How to Find Xanax in Stock Near You.
The Xanax supply situation in 2026 is better than it was at its worst in 2020-2022, but it's still not where it should be. Patients continue to face intermittent shortages driven by DEA quotas, supply chain variability, and high demand.
The best thing you can do is plan ahead. Use Medfinder to find pharmacies with Alprazolam in stock, talk to your doctor about backup plans, and never let your supply run completely out before seeking a refill.
If you're concerned about side effects or drug interactions, we have guides for those too. You're not alone in this — and there are tools to help.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.